Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 883

1.

Predictors of left ventricular remodelling in patients with dilated cardiomyopathy - a cardiovascular magnetic resonance study.

Tayal U, Wage R, Newsome S, Manivarmane R, Izgi C, Muthumala A, Dungu JN, Assomull R, Hatipoglu S, Halliday BP, Lota AS, Ware JS, Gregson J, Frenneaux M, Cook SA, Pennell DJ, Scott AD, Cleland JGF, Prasad SK.

Eur J Heart Fail. 2020 Feb 13. doi: 10.1002/ejhf.1734. [Epub ahead of print]

PMID:
32056322
2.

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.

Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, Ng LL, Anker SD, Samani NJ, Filippatos G, Cleland JG, Zannad F, Hillege HL, van Veldhuisen DJ, Metra M, Voors AA, Mullens W.

Clin Res Cardiol. 2020 Jan 30. doi: 10.1007/s00392-020-01598-w. [Epub ahead of print]

PMID:
32002631
3.

Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.

Lombardi CM, Ferreira JP, Carubelli V, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Voors A, Metra M.

Clin Res Cardiol. 2020 Jan 29. doi: 10.1007/s00392-019-01588-7. [Epub ahead of print]

PMID:
31996990
4.

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.

Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF.

Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1716. [Epub ahead of print]

PMID:
31950604
5.

Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure.

Filippatos G, Angermann CE, Cleland JGF, Lam CSP, Dahlström U, Dickstein K, Ertl G, Hassanein M, Hart KW, Lindsell CJ, Perrone SV, Guerin T, Ghadanfar M, Schweizer A, Obergfell A, Collins SP.

JAMA Cardiol. 2020 Jan 8. doi: 10.1001/jamacardio.2019.5108. [Epub ahead of print]

PMID:
31913404
6.

The year in cardiology: heart failure.

Cleland JGF, Lyon AR, McDonagh T, McMurray JJV.

Eur Heart J. 2020 Jan 6. pii: ehz949. doi: 10.1093/eurheartj/ehz949. [Epub ahead of print] No abstract available.

PMID:
31901936
7.

Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015.

Sundaram V, Bloom C, Zakeri R, Halcox J, Cohen A, Bowrin K, Briere JB, Banerjee A, Simon DI, Cleland JGF, Rajagopalan S, Quint JK.

Eur Heart J. 2019 Dec 28. pii: ehz880. doi: 10.1093/eurheartj/ehz880. [Epub ahead of print]

PMID:
31883328
8.

What do patients with heart failure die from? A single assassin or a conspiracy?

Anker MS, Hülsmann M, Cleland JG.

Eur J Heart Fail. 2020 Jan;22(1):26-28. doi: 10.1002/ejhf.1689. Epub 2019 Dec 21. No abstract available.

PMID:
31863684
9.

Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank.

Welsh C, Welsh P, Celis-Morales CA, Mark PB, Mackay D, Ghouri N, Ho FK, Ferguson LD, Brown R, Lewsey J, Cleland JG, Gray SR, Lyall DM, Anderson JJ, Jhund PS, Pell JP, McGuire DK, Gill JMR, Sattar N.

Diabetes Care. 2020 Feb;43(2):440-445. doi: 10.2337/dc19-1683. Epub 2019 Dec 18.

PMID:
31852727
10.

Selenium and outcome in heart failure.

Bomer N, Grote Beverborg N, Hoes MF, Streng KW, Vermeer M, Dokter MM, IJmker J, Anker SD, Cleland JGF, Hillege HL, Lang CC, Ng LL, Samani NJ, Tromp J, van Veldhuisen DJ, Touw DJ, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Dec 6. doi: 10.1002/ejhf.1644. [Epub ahead of print]

PMID:
31808274
11.

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.

Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, Böhm M, McMurray JJV, Wikstrand J, Anker SD, van Veldhuisen DJ, Manzano L, von Lueder TG, Rigby AS, Andersson B, Kjekshus J, Wedel H, Ruschitzka F, Cleland JGF, Damman K, Redon J, Coats AJS; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2019 Dec 10;74(23):2893-2904. doi: 10.1016/j.jacc.2019.09.059.

12.

Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.

Pandhi P, Ter Maaten JM, Emmens JE, Struck J, Bergmann A, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Cotter G, Davison B, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Dec 3. doi: 10.1002/ejhf.1693. [Epub ahead of print]

PMID:
31797505
13.

Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.

Ferreira JP, Ouwerkerk W, Tromp J, Ng L, Dickstein K, Anker S, Filippatos G, Cleland JG, Metra M, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2020 Jan;22(1):81-89. doi: 10.1002/ejhf.1654. Epub 2019 Dec 2.

PMID:
31793144
14.

Chronic Obstructive Pulmonary Disease and Heart Failure: A Breathless Conspiracy.

Pellicori P, Cleland JGF, Clark AL.

Heart Fail Clin. 2020 Jan;16(1):33-44. doi: 10.1016/j.hfc.2019.08.003. Review.

PMID:
31735313
15.

Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.

Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, Lang CC, Ng LL, van Veldhuisen DJ, Dickstein K, Metra M, Duarte K, Rossignol P, Zannad F, Ferreira JP.

Eur J Intern Med. 2020 Jan;71:62-69. doi: 10.1016/j.ejim.2019.10.017. Epub 2019 Nov 8.

PMID:
31708361
16.

Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease.

Lees JS, Welsh CE, Celis-Morales CA, Mackay D, Lewsey J, Gray SR, Lyall DM, Cleland JG, Gill JMR, Jhund PS, Pell J, Sattar N, Welsh P, Mark PB.

Nat Med. 2019 Nov;25(11):1753-1760. doi: 10.1038/s41591-019-0627-8. Epub 2019 Nov 7.

PMID:
31700174
17.

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.

Cao TH, Jones DJL, Voors AA, Quinn PA, Sandhu JK, Chan DCS, Parry HM, Mohan M, Mordi IR, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Lang CC, Ng LL.

Eur J Heart Fail. 2020 Jan;22(1):70-80. doi: 10.1002/ejhf.1608. Epub 2019 Nov 6.

PMID:
31692186
18.

Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.

Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Ouwerkerk W, van Veldhuisen DJ, Voors AA, van der Meer P.

JACC Heart Fail. 2019 Nov;7(11):970-979. doi: 10.1016/j.jchf.2019.07.010. Epub 2019 Oct 9.

PMID:
31606364
19.

Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis.

Nikolaidou T, Samuel NA, Marincowitz C, Fox DJ, Cleland JGF, Clark AL.

Ann Noninvasive Electrocardiol. 2020 Jan;25(1):e12710. doi: 10.1111/anec.12710. Epub 2019 Oct 11. Review.

PMID:
31603593
20.

Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients With Heart Failure.

Pellicori P, Urbinati A, Kaur K, Zhang J, Shah P, Kazmi S, Capucci A, Cleland JGF, Clark AL.

Am J Cardiol. 2019 Nov 15;124(10):1554-1560. doi: 10.1016/j.amjcard.2019.08.018. Epub 2019 Aug 23.

PMID:
31558271
21.

Temporal Trends and Patterns in Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals.

Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, Salimi-Khorshidi G, Cleland JG, McMurray JJV, Rahimi K.

JAMA Cardiol. 2019 Sep 3. doi: 10.1001/jamacardio.2019.3593. [Epub ahead of print]

22.

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.

Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427.

23.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Oct 5;394(10205):1254-1263. doi: 10.1016/S0140-6736(19)31792-1. Epub 2019 Aug 22.

PMID:
31447116
24.

Effects of Serelaxin in Patients with Acute Heart Failure.

Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stępińska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators.

N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291.

PMID:
31433919
25.

Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure.

Cleland JGF, Pellicori P.

Circulation. 2019 Aug 13;140(7):538-541. doi: 10.1161/CIRCULATIONAHA.119.041523. Epub 2019 Aug 12. No abstract available.

PMID:
31403847
26.

Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial.

Johnson MJ, Cockayne S, Currow DC, Bell K, Hicks K, Fairhurst C, Gabe R, Torgerson D, Jefferson L, Oxberry S, Ghosh J, Hogg KJ, Murphy J, Allgar V, Cleland JGF, Clark AL.

ESC Heart Fail. 2019 Dec;6(6):1149-1160. doi: 10.1002/ehf2.12498. Epub 2019 Aug 6.

27.

Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?

Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt BK.

Eur Heart J. 2019 Aug 6. pii: ehz550. doi: 10.1093/eurheartj/ehz550. [Epub ahead of print]

PMID:
31386109
28.

Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.

Yazaki Y, Salzano A, Nelson CP, Voors AA, Anker SD, Cleland JG, Lang CC, Metra M, Samani NJ, Ng LL, Suzuki T.

Eur J Heart Fail. 2019 Oct;21(10):1291-1294. doi: 10.1002/ejhf.1550. Epub 2019 Jul 28. No abstract available.

PMID:
31353762
29.

High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death.

Pellicori P, Zhang J, Cuthbert J, Urbinati A, Shah P, Kazmi S, Clark AL, Cleland JGF.

Cardiovasc Res. 2020 Jan 1;116(1):91-100. doi: 10.1093/cvr/cvz198.

PMID:
31350553
30.

Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.

Bégué C, Mörner S, Brito D, Hengstenberg C, Cleland JGF, Arbustini E, Galve E, Wichter T, Richter A, Golmard JL, Bernard M, Dubourg O, Komajda M, Charron P, Isnard R.

Heart. 2020 Feb;106(3):196-202. doi: 10.1136/heartjnl-2019-314826. Epub 2019 Jul 26.

PMID:
31350276
31.

When can heart failure treatment be stopped safely? - Authors' reply.

Halliday BP, Cleland JGF, Prasad SK.

Lancet. 2019 Jul 20;394(10194):217-218. doi: 10.1016/S0140-6736(19)30499-4. No abstract available.

PMID:
31327366
32.

New perspectives and future directions in the treatment of heart failure.

Pellicori P, Khan MJI, Graham FJ, Cleland JGF.

Heart Fail Rev. 2020 Jan;25(1):147-159. doi: 10.1007/s10741-019-09829-7. Review.

33.

Trajectories of Changes in Renal Function in Patients with Acute Heart Failure.

Beldhuis IE, Streng KW, van der Meer P, Ter Maaten JM, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Cotter G, Cleland JGF, Davison BA, Givertz MM, Teerlink JR, Bloomfield DM, Voors AA, Damman K.

J Card Fail. 2019 Nov;25(11):866-874. doi: 10.1016/j.cardfail.2019.07.004. Epub 2019 Jul 15.

34.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
35.

The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization.

Cleland JGF, Hindricks G, Petrie M.

Eur Heart J. 2019 Jul 1;40(26):2128-2130. doi: 10.1093/eurheartj/ehz409. No abstract available.

PMID:
31257403
36.

The rise and fall of aspirin in the primary prevention of cardiovascular disease.

Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW.

Lancet. 2019 May 25;393(10186):2155-2167. doi: 10.1016/S0140-6736(19)30541-0. Review.

PMID:
31226053
37.

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr; Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2019 Jun;21(6):715-731. doi: 10.1002/ejhf.1494.

PMID:
31222929
38.

Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972].

Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD.

Eur J Heart Fail. 2019 Jun;21(6):819. doi: 10.1002/ejhf.1480. Epub 2019 May 9. No abstract available.

PMID:
31222927
39.

Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.

Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR, Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP, Sattar N, Welsh P.

Circulation. 2019 Aug 13;140(7):542-552. doi: 10.1161/CIRCULATIONAHA.119.041149. Epub 2019 Jun 20.

40.

Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure.

Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV.

Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6.

PMID:
31168885
41.

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.

Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi: 10.1002/ejhf.1531. Epub 2019 Aug 30.

PMID:
31129923
42.

Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients.

Conrad N, Judge A, Canoy D, Tran J, O'Donnell J, Nazarzadeh M, Salimi-Khorshidi G, Hobbs FDR, Cleland JG, McMurray JJV, Rahimi K.

PLoS Med. 2019 May 21;16(5):e1002805. doi: 10.1371/journal.pmed.1002805. eCollection 2019 May.

43.

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F.

Circ Heart Fail. 2019 May;12(5):e005897. doi: 10.1161/CIRCHEARTFAILURE.118.005897.

44.

Prevention or Procrastination for Heart Failure?: Why We Need a Universal Definition of Heart Failure.

Cleland JGF, Pellicori P, Clark AL.

J Am Coll Cardiol. 2019 May 21;73(19):2398-2400. doi: 10.1016/j.jacc.2019.03.471. No abstract available.

PMID:
31097158
45.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14.

PMID:
31087601
46.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants.

Kidney Int. 2019 Jun;95(6):1304-1317. doi: 10.1016/j.kint.2019.02.022. Epub 2019 Apr 30.

47.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.

PMID:
31017637
48.

Clinical and prognostic association of total atrial conduction time in patients with heart failure: a report from Studies Investigating Co-morbidities Aggravating Heart Failure.

Nuzzi V, Pellicori P, Nikolaidou T, Kallvikbacka-Bennett A, Torromeo C, Barilla' F, Salekin D, Kaur K, Monzo L, Cleland JGF, Clark AL.

J Cardiovasc Med (Hagerstown). 2019 Jul;20(7):442-449. doi: 10.2459/JCM.0000000000000802.

PMID:
30985354
49.

Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit.

Anderson SG, Shoaib A, Myint PK, Cleland JG, Hardman SM, McDonagh TA, Dargie H, Keavney B, Garratt CJ, Mamas MA.

Clin Res Cardiol. 2019 Nov;108(11):1276-1286. doi: 10.1007/s00392-019-01463-5. Epub 2019 Apr 8.

50.

Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema.

Shoaib A, Mamas MA, Ahmad QS, McDonagh TM, Hardman SMC, Rashid M, Butler R, Duckett S, Satchithananda D, Nolan J, Dargie HJ, Clark AL, Cleland JGF.

Int J Cardiol. 2019 Jun 15;285:40-46. doi: 10.1016/j.ijcard.2019.03.020. Epub 2019 Mar 15.

PMID:
30905515

Supplemental Content

Loading ...
Support Center